What Is an AUST L(A) Assessed Listed Medicine?

AUST L(A) Assessed Listed Medicine

ARTG pathway for eligible assessed listed medicines, which receive an AUST L(A) number after the applicable assessment process. This designation sits inside the Australian Register of Therapeutic Goods (ARTG) framework and marks listed medicines that have undergone a formal assessment before an AUST L(A) identifier is allocated.

Assessed listed medicines are a subset of listed (AUST L) medicines created to manage higher‑risk or higher‑impact claims and ingredients without placing them into registered (prescription or higher‑level) categories. The assessment evaluates supporting evidence for safety, quality and advertising claims before the product is recorded in the ARTG with the AUST L(A) prefix. That AUST L(A) number must then be used by sponsors in labelling and advertising to show the product’s assessed status.

Why The AUST L(A) Pathway Exists

The pathway balances consumer protection with access and market efficiency. It lets sponsors bring lower‑risk, non‑prescription therapeutic products to market while subjecting a defined group of listed medicines to a higher scrutiny level than self‑listed (AUST L) products. This targeted oversight is used where claims, ingredients, or public health considerations make a prior assessment appropriate.

What The Assessment Covers

• Claims And Indications: Review of advertising statements and permitted indications to ensure they are supported by evidence and comply with the permitted indications framework.
• Safety And Ingredients: Evaluation of ingredient safety, including concentrations and interactions, and any novel or restricted substances.
• Quality Documentation: Evidence that the product is manufactured to appropriate standards and that specified composition and stability claims are supported.

How It Differs From Standard Listings

Standard listed medicines (AUST L) are placed on the ARTG by sponsors who certify that the product meets regulatory requirements and that they hold evidence to substantiate claims. For AUST L(A) products the TGA performs an assessment of those matters prior to allocation of the AUST L(A) number. That means sponsors of assessed listed medicines cannot rely solely on self‑certification for the features covered by the assessment.

Who Uses The AUST L(A) Designation

The primary users are product sponsors — manufacturers, importers or distributors who are responsible for the ARTG entry and regulatory compliance. Retailers and 3PLs should also be aware of the designation because it affects labelling, advertising and recall expectations. Consumers may see the AUST L(A) identifier on packaging or online product pages and use it as an indicator that the product has been assessed prior to listing.

Practical Example

A supplement with a novel herbal extract and advertising copy that claims benefit for specific symptoms may trigger an assessed listing. The sponsor submits evidence for the extract’s safety and the claim’s support. If the evidence satisfies the TGA, the product is entered onto the ARTG with an AUST L(A) number. The sponsor then uses that number on labels and in advertising; retailers should display the product according to the sponsor’s instructions and be able to reference the ARTG entry if requested.

How It Affects Retailers And Warehouse Operators

• Labelling Checks: Retailers should verify the presence of the AUST L(A) number on products and packaging to confirm the product’s ARTG status.
• Advertising Compliance: If a retailer publishes product descriptions, those descriptions must not contradict the assessed indications or exceed permitted claims.
• Supply Chain Traceability: Maintain records to assist sponsors with post‑market monitoring and recalls, since assessed products attract closer scrutiny.

Common Sponsor Actions And Tips

• Prepare Evidence Early: Collate safety studies, ingredient specifications and claim‑supporting documentation before lodging an application.
• Use The TGA Portal: Lodge applications via the TGA’s electronic submission service and follow the published guidance to avoid administrative delays.
• Label Accurately: Apply the assigned AUST L(A) number exactly as issued and include any mandatory statement elements required by the TGA.

In short, the AUST L(A) Assessed Listed Medicine designation identifies listed therapeutic goods that have passed a pre‑listing assessment and been entered on the ARTG with an AUST L(A) number. For sponsors it means submitting stronger evidence up front; for retailers and warehouse operators it affects labelling, advertising and traceability obligations.